The FDA began a two-day meeting to review peptides, substances gaining attention in the wellness sector despite scant evidence supporting their safety or efficacy. Health Secretary Robert F. Kennedy Jr., an advocate of peptides, aims to change industry limitations imposed under President Joe Biden.
Prominent figures, including podcaster Joe Rogan and influencer Gary Brecka, support these peptides and promote their alleged benefits on social media. Users claim peptides aid muscle growth, injury recovery, and youthful appearance. However, FDA career scientists express doubts due to the lack of comprehensive data, especially concerning peptides from compounding pharmacies.
Compounding pharmacies prepare personalized medications, which traditional drug manufacturers do not offer. This approach faces scrutiny from medical and scientific experts involved in the FDA meeting. Rita Jew, a pharmacist and president of the Institute for Safe Medication Practices, highlights the alarming situation, emphasizing the weak clinical evidence backing the widespread peptide injections.
The FDA’s panel includes professionals with vested interests in the peptide industry, sparking concerns about potential conflicts of interest. Recently, additional experts without industry ties were added to the 20-member panel.
Peptides, fundamental to protein formation, stimulate hormonal activities necessary for growth and healing. Some have been developed into drugs for conditions like diabetes and weight loss. Advocates wish the FDA to permit seven peptides for compounding concerning medical issues such as opioid addiction and ulcerative colitis.
The FDA has previously cautioned against peptides like BPC-157 and TB-500, flagged as doping agents by sports authorities. Regulator reviews show persistent concerns over contamination and allergic reactions, supported mainly by animal studies rather than human trials. FDA staff discourage compounding all seven peptides under review, citing insufficient safety and efficacy data.
The public will also have the opportunity to share their views with the FDA experts. Over 1,900 public comments have been submitted, including testimonials from doctors and patients advocating peptide benefits. The American Academy of Peptide Medicine, an education-focused group, supports the legal and safe access to peptides through regulated pharmacies.
Following the meeting, the FDA will evaluate the expert votes, discussions, and public input before deciding on peptide access. Observers suggest a potential temporary assurance policy for compounding pharmacies. Officially labeling peptides as safe for compounding demands new regulations, requiring extensive time to implement. Attorney Nathan Beaver anticipates alignment with Secretary Kennedy’s goals upon completing this process.
The Associated Press maintains editorial control of content produced by its Health and Science Department, backed by support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation.
Leave a Reply